HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3-phenyl-4,5-dihydro-5-isoxazole acetic acid

structure in first source

Also Known As:

(S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid; GIT27; VGX-1027

Networked: 12 relevant articles (5 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - 3-phenyl-4,5-dihydro-5-isoxazole acetic acid: 12
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Acetates: 4994
      - 3-phenyl-4,5-dihydro-5-isoxazole acetic acid: 12
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - 3-phenyl-4,5-dihydro-5-isoxazole acetic acid: 12

Experts

1.	Nicoletti, Ferdinando: 6 articles (03/2016 - 03/2007)
2.	Mangano, Katia: 4 articles (08/2014 - 03/2007)
3.	Donia, Marco: 3 articles (09/2008 - 06/2007)
4.	Miljkovic, Djordje: 3 articles (09/2008 - 03/2007)
5.	Stosic-Grujicic, Stanislava: 3 articles (09/2008 - 03/2007)
6.	Muthumani, Karuppiah: 2 articles (03/2016 - 08/2014)
7.	Sardesai, Niranjan Y: 2 articles (03/2016 - 08/2014)
8.	Weiner, David B: 2 articles (03/2016 - 08/2014)
9.	Al-Abed, Yousef: 2 articles (09/2008 - 03/2007)
10.	Harhaji, Ljubica: 2 articles (09/2008 - 03/2007)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 03/01/2007 - "A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice." 11/01/2008 - "VGX-1027 is a novel, low molecular weight, immunomodulatory compound that has shown efficacy against a variety of immuno-inflammatory disease models in animals including autoimmune diabetes in NOD mice, collagen-induced arthritis and chemically induced inflammatory colitis. " 03/01/2007 - "The capacity of VGX-1027 to prevent interleukin (IL)-1beta plus interferon-gamma-induced pancreatic islet death in vitro prompted us to evaluate its effects on the development of autoimmune diabetes in preclinical models of human type 1 diabetes mellitus (T1D). " 08/01/2014 - "VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic acid] is a small molecule compound with immunomodulatory properties, which favourably influences the development of immuno-inflammatory and autoimmune diseases in different animal models such as type 1 diabetes mellitus, pleurisy, rheumatoid arthritis and inflammatory bowel disease. "
2.	Inflammation (Inflammations) 01/05/2019 - "Protective effects of VGX-1027 in PM2.5-induced airway inflammation and bronchial hyperresponsiveness." 01/05/2019 - "We investigated the effect of VGX-1027, a TLR4 blocker, on PM2.5-induced airway inflammation and bronchial hyperresponsiveness (BHR) in a murine model in vivo and on inflammatory mechanisms in vitro in human airway epithelial cells. " 01/05/2019 - "VGX-1027 may be a potential prophylactic treatment for PM2.5-induced acute lung injury that has airway inflammation, BHR and mitochondrial damage." 03/01/2007 - "These results indicate that VGX-1027 probably exerts its antidiabetogenic effects by limiting cytokine-mediated immunoinflammatory events, leading to inflammation and destruction of pancreatic islets. "
3.	Colitis 05/31/2008 - "In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027." 05/31/2008 - "The data from the two sets of experiments revealed that VGX-1027 inhibited both proliferation of enterobacterial antigen-reactive CD4+CD25- T cells in vitro and the development of clinical and histological signs of colitis in vivo. " 11/01/2008 - "VGX-1027 is a novel, low molecular weight, immunomodulatory compound that has shown efficacy against a variety of immuno-inflammatory disease models in animals including autoimmune diabetes in NOD mice, collagen-induced arthritis and chemically induced inflammatory colitis. "
4.	Glucose Intolerance 03/01/2014 - "Glucose intolerance, oxidative stress, and lipid abnormalities in HFD mice were improved by GIT27 treatment. "
5.	Obesity 03/01/2014 - "GIT27 ameliorates abnormalities of lipid metabolism and may have renoprotective effects on obesity-related kidney disease through its anti-inflammatory properties." 03/01/2014 - "In addition, GIT27 treatment decreased the urinary excretion of albumin and protein in obesity-related kidney disease, urinary oxidative stress markers, and inflammatory cytokine levels. "

Related Drugs and Biologics

1.	Lipids
2.	Insulin (Novolin)
3.	Nitric Oxide (Nitrogen Monoxide)
4.	Cytokines
5.	Toll-Like Receptor 4
6.	Collagen Type II (Type II Collagen)
7.	Acetic Acid (Vinegar)
8.	Streptozocin (Streptozotocin)
9.	Proteins (Proteins, Gene)
10.	Oligonucleotides

Related Therapies and Procedures

1.	Glycemic Control